Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference
06 Mayo 2024 - 10:30AM
Business Wire
Late-Breaking scientific poster at the American Thoracic Society
Clinical and Scientific sessions will present Vasomune’s Phase 1
safety, and pharmacokinetic and pharmacodynamic data for AV-001
Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical
company focused on the development of AV-001 for the treatment of
diseases associated with vascular dysfunction, today announced that
the Company will present a Late-Breaking scientific poster at the
upcoming 2024 American Thoracic Society (ATS) International
Conference taking place May 17-22, 2024, at the Manchester Grand
Hyatt, San Diego, CA.
Vasomune’s lead drug candidate AV-001, codeveloped with AnGes
Inc, is a first-in-class fully synthetic PEGylated peptide
targeting the Tie2 receptor. Activation of the Tie2 receptor plays
a critical role in promoting vascular stability, barrier integrity
and endothelial quiescence. Activation of the Tie2 receptor by
AV-001 has demonstrated therapeutic potential for the treatment of
pneumonia and acute respiratory distress syndrome resulting from
infection by SARS-CoV-2 or other viral or bacterial pathogens.
AV-001 is currently being researched in NCT05123755, a Phase 2a
study for patients hospitalized with pneumonia.
“Peer-reviewed presentation of our Phase 1 development data is
an important landmark in our development efforts for AV-001” said
Dr. Brian E. Jahns, President and Chief Operating Officer.
“Vasomune is grateful to the National Research Council Canada for
grant #IRAP-965762 which supported the Phase 1 study. Vasomune is
also indebted to the United States Department of Defense
Congressionally Directed Medical Research Programs award #PR191212
for support to advance AV-001 into the clinic.”
Ei Yamada, President & CEO of AnGes, said that “Our Phase 1
trial, NCT04737486, demonstrates that the safety, pharmacokinetics,
and pharmacodynamics of AV-001 support further development. We look
forward to future success with AV-001.”
Clinical and Scientific Sessions
- Date: May 21, 2024
- Presentation Time: 11:30 AM – 1:15 PM PT
- Session (C40): ARDS and Acute Respiratory Failure: Mechanism,
Risk and Outcomes
- Poster: 14798 - A Randomized, Double‑Blind, Placebo‑Controlled
Phase 1 Single and Multiple‑Dose Pharmacokinetic First‑In‑Human
Study of AV‑001 in Healthy Subjects for the Treatment of Acute
Respiratory Distress Syndrome
A copy of the presentation materials can be accessed by visiting
https://vasomune.com/ after the conclusion of the ATS
Conference.
About AV-001
Originally discovered and designed at Sunnybrook Research
Institute at Sunnybrook Hospital in Toronto, AV-001 is being
developed by Vasomune Therapeutics, Inc. under a co-development
agreement with AnGes, Inc. [TYO: 4563]. AV-001 is a novel
investigational medicine that targets the Tie2 receptor, a
transmembrane protein most highly expressed on the surface of
endothelial cells in the vasculature. AV-001 activates the
nonredundant Tie2-Angiopoietin signaling axis, and through
stimulation of multiple downstream pathways normalizes the
vasculature by enhancing endothelial cell stability, restoring
normal barrier defense, and blocking vascular leak. Vascular
dysfunction contributes to the underlying disease pathophysiology
in patients with bacterial and viral acute respiratory distress
syndrome, sepsis, hemorrhagic shock, acute kidney injury, stroke,
and vascular dementia. Importantly, in multiple pre-clinical
studies AV-001 tightened endothelial cell-cell junctions and
promoted endothelial cell survival, which reduced pulmonary edema,
and improved lung function compared to untreated controls
translating into significantly improved survival.
About Vasomune Therapeutics,
Inc.
Vasomune Therapeutics, Inc. is a private clinical-stage
biopharmaceutical company developing the next generation of
medicines to harness the body’s ability to defend against illness.
Founded in 2014, Vasomune has focused on vascular normalization
strategies, and has progressed the lead candidate AV-001 from bench
to bedside. Vascular dysfunction is associated with the pathology
of several disease states, including bacterial and viral acute
respiratory distress syndrome, sepsis, hemorrhagic shock, acute
kidney injury, stroke, and vascular dementia. Vasomune’s corporate
headquarters and laboratories are in Toronto, Canada with US
offices in Raleigh, NC. For more information about the company
please visit www.vasomune.com.
About AnGes, Inc.
AnGes, Inc., a biopharmaceutical company founded in December
1999, focuses on the development of gene-based medicines. In March
2019, AnGes obtained conditional and time-limited approval for its
lead product, Collategene® (Hepatocyte Growth Factor; HGF—plasmid
gene therapy), for the treatment of lower limb ischemic ulcers. In
September 2019, AnGes commenced commercialization in Japan of
Collategene®, the world’s first marketed drug using plasmid DNA.
AnGes is currently working on the development of a Tie2 tyrosine
kinase receptor agonist (AV-001) for COVID-19, viral and
bacterial-associated pneumonia and an NF-κB decoy oligonucleotide
for chronic discogenic lumbar back pain. Furthermore, AnGes
acquired EmendoBio in December 2020 to expand its capabilities in
genome-editing technologies. For more information, visit
https://www.anges.co.jp/en/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506279014/en/
Media: Shahid Ahmad, Vice-President Operations and
Planning Lauren Jahns, Associate Vasomune Media Relations (647)
475-5663 media@vasomune.com